KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Operating Leases: 2018-2025

Historic Operating Leases for Moderna (MRNA) over the last 6 years, with Sep 2025 value amounting to $677.0 million.

  • Moderna's Operating Leases fell 3.29% to $677.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $677.0 million, marking a year-over-year decrease of 3.29%. This contributed to the annual value of $671.0 million for FY2024, which is 4.35% up from last year.
  • Latest data reveals that Moderna reported Operating Leases of $677.0 million as of Q3 2025, which was down 0.73% from $682.0 million recorded in Q2 2025.
  • Over the past 5 years, Moderna's Operating Leases peaked at $730.0 million during Q3 2023, and registered a low of $92.0 million during Q4 2022.
  • For the 3-year period, Moderna's Operating Leases averaged around $582.0 million, with its median value being $677.0 million (2025).
  • Its Operating Leases has fluctuated over the past 5 years, first fell by 13.21% in 2022, then spiked by 598.91% in 2023.
  • Moderna's Operating Leases (Quarterly) stood at $106.0 million in 2021, then decreased by 13.21% to $92.0 million in 2022, then soared by 598.91% to $643.0 million in 2023, then rose by 4.35% to $671.0 million in 2024, then fell by 3.29% to $677.0 million in 2025.
  • Its Operating Leases was $677.0 million in Q3 2025, compared to $682.0 million in Q2 2025 and $682.0 million in Q1 2025.